Share This Page
Drug Price Trends for NDC 00013-5301
✉ Email this page to a colleague
Average Pharmacy Cost for 00013-5301
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00013-5301
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00013-5301
Introduction
The drug identified by NDC 00013-5301 refers to Revlimid (lenalidomide), a therapeutic agent primarily indicated for multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes. As one of the flagship products in the oncology treatment landscape, Revlimid possesses a complex market profile characterized by high demand, patent protections, and a competitive pharmacy benefit environment. This analysis examines the current market dynamics, historical pricing trends, and projected price trajectories for Revlimid, offering insights pivotal to stakeholders including pharmaceutical companies, investors, healthcare providers, and policymakers.
Market Overview
Product Profile
Revlimid (lenalidomide) is a cornerstone immunomodulatory agent initially developed by Celgene, later acquired by Bristol-Myers Squibb. Its pharmacological efficacy in hematologic malignancies has sustained high demand since its approval in 2005 for multiple myeloma. The drug’s patent protections, including exclusive marketing rights through 2026 in the United States, have played a key role in maintaining a monopolistic pricing structure.
Market Size and Growth Drivers
The global multiple myeloma market was valued at approximately USD 18 billion in 2021 and is expected to grow at a CAGR of 8–10% through 2027, driven by aging populations, improved diagnosis rates, and evolving combination therapy regimens involving Revlimid [1]. In the U.S., the drug's revenue surpassed USD 6 billion annually, making it one of the top-selling oncology drugs.
Key growth drivers include:
- Expanded indications: Ongoing clinical trials could potentially expand Revlimid’s approved uses.
- Line of therapy: Evolving treatment protocols favor Revlimid’s use as first-line therapy.
- Pricing power: Tight patent protection and lack of biosimilar competitors ensure sustained pricing.
Competitive Landscape
Despite the impending patent expiry risks post-2026, the current market benefits from high barriers to entry for biosimilars and generics. Multiple biosimilar candidates are in development, yet regulatory hurdles and market inertia have delayed significant price erosion.
Pricing Trends and Historical Data
Current Pricing
As a branded formulary drug, the average wholesale price (AWP) for Revlimid has historically ranged from USD 12 to 14 per capsule, depending on dosage and packaging size. A typical regimen involves daily administration over multiple months, resulting in substantial treatment costs. According to the SSR Health report (2022), the average annual patient expense for Revlimid is approximately USD 130,000–150,000, reflecting high-cost therapy status.
Price Trends
Over the past decade, Revlimid’s price has increased steadily, with annual price hikes averaging 5–7%. These hikes are primarily driven by inflation-based adjustments and the monopolistic market structure. Market share retention has been supported through payer negotiations, utilization management strategies, and value-based contracting where applicable.
Post-2015, some moderation in price increases was observed due to insurance formulary shifts and introduction of biosimilar candidates, yet significant downward pressure has not materialized. The COVID-19 pandemic temporarily destabilized supply chains but did not appreciably affect retail price points.
Future Price Projections
Pre-Patent Expiry Period (2023–2026)
Given the current market context, Revlimid's price is projected to remain relatively stable through 2026. Manufacturers are likely to sustain premium pricing fueled by:
- High demand in indication expansion.
- Payer resistance to price reductions.
- Limited biosimilar competition until patent expiration.
Analysts forecast a compounded annual growth rate (CAGR) of 2–3% in the wholesale price, factoring in inflation and negotiated discounts. The total treatment cost may increase modestly, especially as dosing regimens evolve toward combination therapies.
Post-Patent Expiry Scenario (2027 and beyond)
Entering the post-patent era, significant price erosion is expected due to biosimilar proliferation. Conservative estimates suggest:
- Biosimilar market entry could reduce Revlimid’s price by 40–60%.
- Market penetration may initially be slow, as brand loyalty and formulary preferences persist.
- Price stabilization at about 40–50% of current levels within 2–3 years of biosimilar availability.
This transition period will be crucial for stakeholders to recalibrate strategies. Innovative contractual models, such as value-based pricing, may soften the impact.
Influencing Factors
Multiple external parameters will influence actual prices:
- Regulatory approval timelines for biosimilars.
- Payer reimbursement policies.
- Competitive landscape shifts.
- Legal challenges to patent protections.
Market Risks and Opportunities
Risks
- Patent litigation delays or invalidations could accelerate biosimilar competition.
- Payer pushback on high-cost therapies might limit access or negotiations.
- Development of alternative agents with similar efficacy could fragment the market.
Opportunities
- Early adoption of biosimilar formulations could secure market share.
- Strategic alliances with payers to develop value-based contracts.
- Expanded indications and combination therapies could justify premium pricing pre-patent expiry.
Conclusion and Implications
Revlimid (NDC 00013-5301) continues to command a dominant market position due to its proven efficacy, entrenched patents, and limited biosimilar competition. Its pricing is projected to remain relatively stable through 2026, reflecting the drug’s critical role in hematology. Post-2027, a notable price decline is anticipated with market entry of biosimilars, altering the landscape for stakeholders.
Market participants should prepare for these shifts by investing in biosimilar development, forging flexible payer arrangements, and exploring indications beyond current approvals to extend market longevity.
Key Takeaways
- Stable high pricing for Revlimid is expected through 2026 due to strong patent protections.
- Price erosion likely post-2026, with biosimilars reducing costs by up to 60%.
- Market growth driven by increasing prevalence of multiple myeloma and treatment expansion.
- Strategic opportunities exist in biosimilar adoption, innovative contracting, and indication expansion.
- Stakeholders must monitor patent litigation, regulatory pathways, and payer policies for future planning.
FAQs
1. When does Revlimid (lenalidomide) lose patent protection, and what implications does this have?
Patent protections are expected to expire in 2026 in the U.S., paving the way for biosimilar competition that could significantly reduce pricing and impact revenue streams.
2. How much are biosimilars expected to reduce Revlimid’s price post-patent expiry?
Analyses project biosimilars could decrease drug prices by approximately 40–60%, leading to substantially lower treatment costs and opportunities for market penetration.
3. What factors could delay biosimilar market entry?
Regulatory hurdles, patent litigation, and manufacturing complexities can delay biosimilar approval and commercialization, extending Revlimid’s market dominance.
4. Are there ongoing clinical trials that could expand Revlimid’s indications?
Yes, multiple trials are exploring Revlimid in combination therapies and new blood cancers. These could extend market applicability and justify premium pricing pre-2026.
5. How should pharmaceutical companies prepare for the post-2026 landscape?
Investment in biosimilar R&D, strategic partnerships, and diversified indication development are critical to maintain competitiveness after patent expiration.
References
[1] MarketWatch, "Global Multiple Myeloma Market Analysis," 2022.
[2] SSR Health, "Prescription Drug Price Trends," 2022.
[3] IQVIA, "Pharmaceutical Market Insights," 2022.
[4] FDA and Market Regulatory Reports, 2023.
More… ↓
